Roivant Sciences (ROIV) catalysts

FreeBioList tracks 7 catalysts for Roivant Sciences (ROIV, listed on Nasdaq): 6 upcoming and 1 decided. They cover 3 programmes: Brepocitinib (Non-infectious uveitis; Cutaneous sarcoidosis), IMVT-1402 (Cutaneous lupus erythematosus; Difficult-to-treat rheumatoid arthritis; Graves’ disease and myasthenia gravis; CIDP and Sjögren’s disease) and Mosliciguat (Pulmonary hypertension with interstitial lung disease).

First on the list: the Phase 3 readout for Brepocitinib (Non-infectious uveitis), guided by the company to H2 2026. The furthest-out event tracked is 2028. By stage, the upcoming rows are 1 Phase 2 readout and 5 Phase 3 readouts.

Decided and on record:

• Mosliciguat, Phase 2 readout: Positive topline, announced 8 September 2026.

Each outcome links to the filing or notice that reported it in the table below.

All 7 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 14 Sep 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout; Clinical trial phases explained: Phase 1 to Phase 4.